Leo Pharma pays $50M for Replay and its preclinical skin disease gene therapy
Leo Pharma pays $50M for Replay and its preclinical skin disease gene therapy
Leo Pharma pays $50M for Replay and its preclinical skin disease gene therapy
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.